Early changes in prefrontal activity characterize clinical responders to antidepressants

Neuropsychopharmacology

Volumn 27, Issue 1, 2002, Pages 120-131

  Cook, Ian A ^a,b   Leuchter, Andrew F ^a   Morgan, Melinda ^a   Witte, Elise ^a   Stubbeman, William F ^a   Abrams, Michelle ^a   Rosenberg, Susan ^a   Uijtdehaage, Sebastian H J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant response; Cordance; Depression; EEG; Prefrontal; Response prediction

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BRAIN REGION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; SINGLE-BLIND METHOD;

EID: 0036285108     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00294-4     Document Type: Article

References (57)

1. Plasma serotonin level after 1 day of fluoxetine treatment: A biological predictor for antidepressant response?
2. Single photon emission tomography with 99mTc-exametazime in major depression and the pattern of brain activity underlying the psychotic/neurotic continuum
3. Reduction of prefrontal cortex glucose metabolism common to three types of depression
4. Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain
5. Pathophysiological significance of cerebral perfusion abnormalities in major depression-trait or state marker?
6. Increased cerebral blood flow in depressed patients responding to electroconvulsive therapy
7. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine
8. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: Preliminary findings
9. Prefrontal changes and treatment response prediction in depression
10. Altered cerebral energy utilization in late life depression
11. Assessing the accuracy of topographic EEG mapping for determining local brain function
12. Neurophysiologic predictors of treatment response to fluoxetine in major depression
13. Stimulation of immediate early gene expression by desipramine in rat brain
14. Geriatric depression: Brain imaging correlates and pharmacologic considerations
15. PET imaging of serotonin 1A receptor binding in depression
16. Subgenual prefrontal cortex abnormalities in mood disorders
17. Neuroanatomical circuits in depression: Implications for treatment mechanisms
18. Cerebral perfusion changes with antidepressant repsone in major depression
19. Executive dysfunction predicts nonresponse to fluoxetine in major depression
20. Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies
21. Pharmaco-EEG profile of levoprotiline: Second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs
22. EEG analysis based on time domain properties
23. An on-line transformation of EEG scalp potentials into orthogonal source derivations
24. Regional cerebral glucose metabolism in major depressive disorder
25. Initiation and adaptation: A paradigm for understanding psychotropic drug action
26. CNS effects of citalopram, a new serotonin inhibitor antidepressant (a quantitative pharmaco-electroencephalography study)
27. Neurometrics: Computer-assisted differential diagnosis of brain dysfunctions
28. Prefrontal dysfunction and treatment response in geriatric depression
29. Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs
30. Quantitative EEG in the prediction of antidepressant response to imipramine
31. Cordance: A new method of assessment of cerebral perfusion and metabolism using quantitative Electroencephalography
32. Assessment of cerebral perfusion and metabolism using Quantitative EEG Cordance
33. Regional differences in brain electrical activity in dementia: Use of spectral power and spectral ratio measures
34. Brain structure and function, and the outcomes of treatment for depression
35. Relationship between brain electrical activity and cortical perfusion in normal subjects
36. Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects
37. Left prefrontal glucose hypometabolism in the depressed state: A confirmation
38. Influence of fluoxetine on regional serotonin synthesis in the rat brain
39. Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation
40. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)
41. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
42. Clinical response to antidepressants is associated with reduced frontal CBF in late-life depression
43. Regional cerebral blood flow in mood disorders, III. Treatment and clinical response
44. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture
45. Acute and short-term effects of ECT on regional cerebral blood flow - a marker of treatment adequacy?
46. The pharmacokinetics of nomifensine. Comparison of pharmacokinetics and pharmacodynamics using computer pharmaco-EEG
47. Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine
48. Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG, and psychometric analyses
49. On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine
50. Topographic brain mapping of EEG in neuropsychopharmacology-Part II. Clinical applications (pharmaco EEG imaging)
51. Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects
52. Quantitative EEG in human neuropharmacology. Rationale, history, and recent developments
53. Topographic approaches in human quantitative pharmaco-electroencephalography
54. New perspectives on the molecular pharmacology of affective disorders
55. EEG characteristics of clinically defined on-drug-responders and non-responders - A comparison clomipramine vs. maprotiline
56. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labeled setoperone